Protagen to Support Pfizer Clinical Drug Development
News Dec 03, 2013

Under the collaboration, Protagen will use its proprietary SeroTag® process to attempt to discover prediction or patient stratification markers for a novel drug being developed by Pfizer.
Protagen CEO Stefan Müllner comments, “The current agreement shows that the SeroTag® process of Protagen is relevant technology to explore novel biomarkers in support of clinical development in inflammatory and autoimmune diseases. We look forward to a productive and collaborative relationship with Pfizer's R&D team.”
RELATED ARTICLES
Understanding Inflammation From the Inside Out
NewsResearchers have developed a method that enables them to genetically modify immune cells, multiply them and visualize them in living organisms. The technique will better evaluate and study the the inflammatory process.
READ MOREThe Immune System's Influence on Brain Development Reviewed
NewsResearchers have highlighted a link between fetal brain development and the origins of developmental diseases such as schizophrenia.
READ MOREDeficiency of Innate Immune Adaptor TRIF Linked to Neurodegeneration
NewsResearch has revealed that deficiency of the innate immune adaptor TRIF, which is essential for certain Toll-like receptor signaling cascades, significantly shortened survival time of ALS mice.
READ MOREComments | 0 ADD COMMENT
Like what you just read? You can find similar content on the communities below.
Immunology & MicrobiologyTo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREEWorld Congress on Advanced Biomaterials and Tissue Engineering
Jun 20 - Jun 21, 2018
Login
You must be logged in to post a comment.